pharmacovigilance risk-benefit optimisation … november 2010 pharmacovigilance regulatory science...

Post on 07-Apr-2018

223 Views

Category:

Documents

2 Downloads

Preview:

Click to see full reader

TRANSCRIPT

www.pharminvent.com November2010

Pharmacovigilance

Regulatory Science

Risk Management

Risk-benefit optimisation

Advanced Therapies

Biologics

Biosimilars

Generics

Small molecules

Centrally authorised

Decentralised procedures

Mutually recognised

Nationally authorised

www.pharminvent.com November2010

PharmInvent is led by experienced

EU ex-regulators, including former

members of CHMP and PhVWP, EMA

managers, as well as ICH and CIOMS

expert group members.

top related